Earnings ·
Jazz Pharmaceuticals reports Q3 revenue of $1.2B, raises full-year guidance to $4.775-$4.85B
JAZZJazz Pharmaceuticals plc
Jazz Pharmaceuticals reported third-quarter 2026 total revenues of $1.2 billion, a 10% increase year-over-year, driven by strong performance from Xywav and Zepzelca. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion. In capital markets activities, Jazz completed a private placement of $1.25 billion in 1.875% exchangeable senior notes due 2032 and repurchased $225 million of ordinary shares, exhausting its prior buyback program while initiating a new $500 million authorization. The quarter also saw the closing of the Actio Biosciences acquisition, adding ABS-1230 to its rare epilepsy pipeline. Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing therapies for rare diseases.